Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK-7975A 是具有口服活性的高效CRAC 通道抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 328 | 现货 | ||
5 mg | ¥ 689 | 现货 | ||
10 mg | ¥ 1,120 | 现货 | ||
25 mg | ¥ 2,250 | 现货 | ||
50 mg | ¥ 3,380 | 现货 | ||
100 mg | ¥ 4,970 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 773 | 现货 |
产品描述 | GSK-7975A is a potent and orally available inhibitor of CRAC channel. |
体外活性 | GSK-7975A inhibits toxin-induced activation of ORAI1 and/or activation of Ca2+ currents after Ca2+ release, in a concentration-dependent manner, in mouse and human pancreatic acinar cells (inhibition >90% of the levels observed in control cells). GSK-7975A inhibits mediator release from mast cells, and pro-inflammatory cytokine release from T-cells in a variety species and it also completely inhibits calcium influx through CRAC channels. This leads to inhibition of the release of mast cell mediators and T-cell cytokines from multiple human and rat preparations. GSK-7975A decreases FcεRI-dependent Ca2+ influx and 3 μM GSK-7975A decreases the release of histamine, leukotriene C4, and cytokines (IL-5/-8/-13 and TNFα) by up to 50%[1]. Mast cells from guinea-pig and mouse preparations are not inhibited by GSK-7975A; however cytokine release is fully blocked from T-cells in a mouse preparation[2]. GSK-7975A also prevents activation of the necrotic cell death pathway in mouse and human pancreatic acinar cells[3]. |
体内活性 | GSK-7975A obviously decreses increases in serum amylase, IL6, and pancreatic MPO levels; lung MPO is reduced significantly by low dose only. GSK-7975A inhibits local and systemic features of acute pancreatitis in TLCS-AP, CER-AP, FAEE-AP, in dose- and time-dependent manners. GSK-7975A markedly decreases pancreatic histopathology in TLCS-AP, CER-AP, and FAEE-AP[3]. |
分子量 | 397.3 |
分子式 | C18H12F5N3O2 |
CAS No. | 1253186-56-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL (201.36 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.517 mL | 12.5849 mL | 25.1699 mL | 62.9247 mL |
5 mM | 0.5034 mL | 2.517 mL | 5.034 mL | 12.5849 mL | |
10 mM | 0.2517 mL | 1.2585 mL | 2.517 mL | 6.2925 mL | |
20 mM | 0.1258 mL | 0.6292 mL | 1.2585 mL | 3.1462 mL | |
50 mM | 0.0503 mL | 0.2517 mL | 0.5034 mL | 1.2585 mL | |
100 mM | 0.0252 mL | 0.1258 mL | 0.2517 mL | 0.6292 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
GSK-7975A 1253186-56-9 Membrane transporter/Ion channel Metabolism Calcium Channel Ca channels GSK 7975A inhibit Inhibitor Ca2+ channels GSK7975A inhibitor